255 related articles for article (PubMed ID: 20563247)
21. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
22. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
23. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
24. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
25. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
26. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
27. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Gamba S; Camaj P; Heinemann V; Laubender RP; Wang Y; Zhao Y; Stintzing S; Giessen C; Boeck S; Haertl C; Bruns CJ; Modest DP
Anticancer Drugs; 2015 Apr; 26(4):371-8. PubMed ID: 25514114
[TBL] [Abstract][Full Text] [Related]
28. Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Janakiraman M; Vakiani E; Zeng Z; Pratilas CA; Taylor BS; Chitale D; Halilovic E; Wilson M; Huberman K; Ricarte Filho JC; Persaud Y; Levine DA; Fagin JA; Jhanwar SC; Mariadason JM; Lash A; Ladanyi M; Saltz LB; Heguy A; Paty PB; Solit DB
Cancer Res; 2010 Jul; 70(14):5901-11. PubMed ID: 20570890
[TBL] [Abstract][Full Text] [Related]
29. EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells.
Martínez-Palacián A; Del Castillo G; Herrera B; Fernández M; Roncero C; Fabregat I; Sánchez A
Cell Signal; 2012 Feb; 24(2):505-513. PubMed ID: 22001397
[TBL] [Abstract][Full Text] [Related]
30. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling.
Ponsioen B; Post JB; Buissant des Amorie JR; Laskaris D; van Ineveld RL; Kersten S; Bertotti A; Sassi F; Sipieter F; Cappe B; Mertens S; Verlaan-Klink I; Boj SF; Vries RGJ; Rehmann H; Vandenabeele P; Riquet FB; Trusolino L; Bos JL; Snippert HJG
Nat Cell Biol; 2021 Apr; 23(4):377-390. PubMed ID: 33795873
[TBL] [Abstract][Full Text] [Related]
31. EGFR Blockade Reverts Resistance to KRAS
Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
[TBL] [Abstract][Full Text] [Related]
32. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
33. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
34. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
35. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis.
Kaulfuss S; Burfeind P; Gaedcke J; Scharf JG
Mol Cancer Ther; 2009 Apr; 8(4):821-33. PubMed ID: 19372555
[TBL] [Abstract][Full Text] [Related]
36. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Mancl EE; Kolesar JM; Vermeulen LC
Am J Health Syst Pharm; 2009 Dec; 66(23):2105-12. PubMed ID: 19923311
[TBL] [Abstract][Full Text] [Related]
37. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.
Chang DZ; Kumar V; Ma Y; Li K; Kopetz S
J Hematol Oncol; 2009 Apr; 2():18. PubMed ID: 19386128
[TBL] [Abstract][Full Text] [Related]
38. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
39. [Predictive biomarkers for anti-EGFR antibodies].
Bando H; Yoshino T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1618-25. PubMed ID: 23152013
[TBL] [Abstract][Full Text] [Related]
40. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
van Krieken JH; Jung A; Kirchner T; Carneiro F; Seruca R; Bosman FT; Quirke P; Fléjou JF; Plato Hansen T; de Hertogh G; Jares P; Langner C; Hoefler G; Ligtenberg M; Tiniakos D; Tejpar S; Bevilacqua G; Ensari A
Virchows Arch; 2008 Nov; 453(5):417-31. PubMed ID: 18802721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
